Paradox-driven adventures in the development of cancer immunology and immunotherapy

Whitney Barham, Joanina K. Gicobi, Yiyi Yan, Roxana S Dronca, Haidong M Dong

Research output: Contribution to journalReview article

Abstract

After more than one hundred years of documented trials, immunotherapy has become a standard of care in the treatment of human cancer. Much of the knowledge that led to recent breakthroughs seems quite logical from today's point of view. However, what we now cite as facts were originally considered paradoxes, meaning something contrary to expectations or perceived opinion at the time. In order to make gains in the field of immunotherapy, one had to be willing to confront ideas and concepts that seemed to contradict one another, and reconcile how each could be true. This is what led to new knowledge and advances. Here, we highlight some of these paradoxes and the milestone discoveries that followed, each one critical for our understanding of immune checkpoint pathways. By outlining some of the steps that we took and the challenges that we overcame, we hope to inspire and encourage future generations of researchers to confront the paradoxes that still permeate the field.

Original languageEnglish (US)
JournalGenes and Diseases
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Immunology
Allergy and Immunology
Immunotherapy
Social Responsibility
Standard of Care
Neoplasms
Research Personnel
Therapeutics

Keywords

  • Biomarker
  • Cancer immunotherapy
  • Cytotoxic T cells
  • Hyperprogression
  • Immune checkpoints
  • PD-1
  • PD-L1

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics(clinical)
  • Cell Biology

Cite this

Paradox-driven adventures in the development of cancer immunology and immunotherapy. / Barham, Whitney; Gicobi, Joanina K.; Yan, Yiyi; Dronca, Roxana S; Dong, Haidong M.

In: Genes and Diseases, 01.01.2019.

Research output: Contribution to journalReview article

@article{26fdb4dba43e4ab4ba2cb609d772925c,
title = "Paradox-driven adventures in the development of cancer immunology and immunotherapy",
abstract = "After more than one hundred years of documented trials, immunotherapy has become a standard of care in the treatment of human cancer. Much of the knowledge that led to recent breakthroughs seems quite logical from today's point of view. However, what we now cite as facts were originally considered paradoxes, meaning something contrary to expectations or perceived opinion at the time. In order to make gains in the field of immunotherapy, one had to be willing to confront ideas and concepts that seemed to contradict one another, and reconcile how each could be true. This is what led to new knowledge and advances. Here, we highlight some of these paradoxes and the milestone discoveries that followed, each one critical for our understanding of immune checkpoint pathways. By outlining some of the steps that we took and the challenges that we overcame, we hope to inspire and encourage future generations of researchers to confront the paradoxes that still permeate the field.",
keywords = "Biomarker, Cancer immunotherapy, Cytotoxic T cells, Hyperprogression, Immune checkpoints, PD-1, PD-L1",
author = "Whitney Barham and Gicobi, {Joanina K.} and Yiyi Yan and Dronca, {Roxana S} and Dong, {Haidong M}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.gendis.2019.07.001",
language = "English (US)",
journal = "Genes and Diseases",
issn = "2352-3042",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Paradox-driven adventures in the development of cancer immunology and immunotherapy

AU - Barham, Whitney

AU - Gicobi, Joanina K.

AU - Yan, Yiyi

AU - Dronca, Roxana S

AU - Dong, Haidong M

PY - 2019/1/1

Y1 - 2019/1/1

N2 - After more than one hundred years of documented trials, immunotherapy has become a standard of care in the treatment of human cancer. Much of the knowledge that led to recent breakthroughs seems quite logical from today's point of view. However, what we now cite as facts were originally considered paradoxes, meaning something contrary to expectations or perceived opinion at the time. In order to make gains in the field of immunotherapy, one had to be willing to confront ideas and concepts that seemed to contradict one another, and reconcile how each could be true. This is what led to new knowledge and advances. Here, we highlight some of these paradoxes and the milestone discoveries that followed, each one critical for our understanding of immune checkpoint pathways. By outlining some of the steps that we took and the challenges that we overcame, we hope to inspire and encourage future generations of researchers to confront the paradoxes that still permeate the field.

AB - After more than one hundred years of documented trials, immunotherapy has become a standard of care in the treatment of human cancer. Much of the knowledge that led to recent breakthroughs seems quite logical from today's point of view. However, what we now cite as facts were originally considered paradoxes, meaning something contrary to expectations or perceived opinion at the time. In order to make gains in the field of immunotherapy, one had to be willing to confront ideas and concepts that seemed to contradict one another, and reconcile how each could be true. This is what led to new knowledge and advances. Here, we highlight some of these paradoxes and the milestone discoveries that followed, each one critical for our understanding of immune checkpoint pathways. By outlining some of the steps that we took and the challenges that we overcame, we hope to inspire and encourage future generations of researchers to confront the paradoxes that still permeate the field.

KW - Biomarker

KW - Cancer immunotherapy

KW - Cytotoxic T cells

KW - Hyperprogression

KW - Immune checkpoints

KW - PD-1

KW - PD-L1

UR - http://www.scopus.com/inward/record.url?scp=85070689630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070689630&partnerID=8YFLogxK

U2 - 10.1016/j.gendis.2019.07.001

DO - 10.1016/j.gendis.2019.07.001

M3 - Review article

AN - SCOPUS:85070689630

JO - Genes and Diseases

JF - Genes and Diseases

SN - 2352-3042

ER -